Q1 2026 · 13F-HR
BOONE CAPITAL MANAGEMENT LLCholdings as filed
Filed 2026-05-15 · accession 0001214659-26-006448
$326.4M
Reported value
13
Positions
2026-03-31
Period end
The Brief · BOONE CAPITAL MANAGEMENT LLC · Q1 2026
AI · grounded in 13F
BOONE CAPITAL MANAGEMENT LLC established a new position in TFX valued at $33.3M. The fund also opened new stakes in GRDN for $23.8M and ASTRAZENECA PLC for $21.7M. On the sell side, the manager closed its position in NBIX, reducing exposure by $21.5M. Additional exits included HQY and RAPT.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $38.9M | 11.9% | 421,236 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $37.6M | 11.5% | 500,522 | Common | SOLE |
| 125523100 | CI | THE CIGNA GROUP | $36.7M | 11.2% | 137,522 | Common | SOLE |
| G5960L103 | MDT | MEDTRONIC PLC | $34.5M | 10.6% | 398,065 | Common | SOLE |
| 879369106 | TFX | TELEFLEX INCORPORATED | $33.3M | 10.2% | 278,792 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $30.9M | 9.48% | 547,871 | Common | SOLE |
| 40145W101 | GRDN | GUARDIAN PHARMACY SVCS INC | $23.8M | 7.28% | 631,193 | Common | SOLE |
| G0593M107 | AZN | ASTRAZENECA PLC | $21.7M | 6.65% | 110,101 | Common | SOLE |
| 91324P102 | UNH | UNITEDHEALTH GROUP INC | $21.4M | 6.57% | 79,226 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $17.0M | 5.21% | 228,829 | Common | SOLE |
| 05350V106 | AVNS | AVANOS MED INC | $16.6M | 5.09% | 1,184,909 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $10.7M | 3.29% | 281,332 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $3.2M | 0.98% | 200,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.